Pfizer and Headlands Health Partner to Increase Clinical Trial Diversity

Clinical trial participants are often far less diverse than the populations they represent, as clinical trial sites are often located in wealthier urban areas. To help solve this problem, Pfizer and Headlands Research have partnered to initiate research sites in more diverse areas. The first such site is in Brownsville, Texas, with more to come in the following years.

According to Paul Schloesser of Endpoints News, “Diversity is an area where Pfizer has struggled in the past, especially after publishing clinical trial diversity data around this time last year. As an example, Black or African American participants made up 14.3% of 212 trials where racial data was collected between 2011 and 2020, according to Pfizer at the time. Contextually, Black Americans represent about 13.4% of the US population. However, when broken down by trial, just less than half of Pfizer’s studies (56.1%) surpassed census levels for Black participants.”

To learn more, click here.

(Source: Endpoints News, May 19^th, 2022)